Southern California father in coma while abroad; family desperate to bring him home
A Southern California family is desperate to bring their father home, who remains in a coma after suffering a medical emergency while traveling abroad.
Loved ones said Manuel Contreras, 47, a father of three from Victorville, loves traveling and spending time with his family.
He recently flew to Cancun, Mexico, to visit a childhood friend. However, during the trip, he initially suffered a small stroke, which was followed by a much larger stroke two days later.
He was rushed to the hospital, where he remains in a coma and in critical condition.
'My dad, he's probably the most hardworking, most active person I know,' Manuel's son, Gabriel Contreras, told KTLA's Shelby Nelson. 'He was going to be gone for a week and it was just to spend time with his friend.'
Manuel's children were notified of their father's hospitalization on May 30.
'I believe he collapsed and luckily, there was someone there to be of assistance,' Contreras said. 'Once the ambulance came to assist my dad to the hospital, his friend was able to meet him there.'
Since then, Manuel's children said they've been met with one heartbreaking challenge after another.
Manuel is currently on Medi-Cal in the United States. The hospital in Mexico that could properly treat his condition would not accept his insurance, so he was transferred to a general hospital instead.
'At the general hospital, they don't have the adequate funding or equipment to treat him there, so they're just putting him into an induced coma and hoping his body heals,' said Ralene Contreras, Manuel's daughter.
His family is now desperately working to bring him back to the U.S. to receive proper medical care, but the cost of transporting him from overseas is extremely high and beyond what they could ever afford.
'Flying him to Houston will cost about $30,000 to get him just into the States to get treated,' Ralene said.
Loved ones have set up a GoFundMe page in hopes of raising money to bring Manuel back. They've also contacted their local congressman, Jay Obernolte, and the U.S. embassy for help, but said they've received no response.
In addition to the stroke, loved ones said Manuel is also suffering from a respiratory infection. With time running out, his children said they are trying to stay hopeful that their father could recover, but are also desperate to bring him back home.
'He's always by his phone because just in case his kids call, he always wants to be the first one there to help them,' Ralene said tearfully. 'I feel helpless knowing that if I call his phone, he's not going to answer.'
'We don't want to think about the worst,' Gabriel said. 'We want to think about the best possible outcome. We know my dad is a very strong man.'
A GoFundMe page to help with Manuel's medical transport costs can be found here.
A raffle fundraiser will also be held at Bombshells Bar & Grill in Victorville on Friday, June 6 at 6 p.m. with raffle prizes.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%. "Today's strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults. The severity of this past flu season underscores the need for more effective vaccines," said Stéphane Bancel, Chief Executive Officer of Moderna. "An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines." In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. [1] According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work. [3] P304 ( NCT06602024 ) is a Phase 3, randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months. Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. [4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported. There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest. Moderna plans to present these data at an upcoming medical conference and submit for peer-reviewed publication. The Company will engage with regulators on filing submissions for mRNA-1010. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's engagement with regulators on filing submissions for its standalone flu vaccine candidate; and the efficacy, safety and tolerability of mRNA-1010. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at . Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris RidleyHead of Global Media Relations+1 Investors: Lavina TalukdarSenior Vice President & Head of Investor Relations+1 [1] [2] [3] [4] SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Miami Herald
4 hours ago
- Miami Herald
Americans Are Using Crowdfunding to Pay for College
Mackenzie Brown is pursuing her dream of becoming a nurse thanks to the kindness of strangers. The 25-year-old, who is in an accelerated program at the Galen College of Nursing in Nashville, Tennessee, had initially relied on financial aid to cover her tuition and expenses. But she was told that was no longer an option after she took a break from her studies following a miscarriage last year, she told Newsweek. Struggling to afford her tuition, she decided to set up a GoFundMe page. Brown is among a growing number of students in the United States turning to crowdfunding to help them overcome the financial barriers to pursuing a college education, as tuition costs continue to soar and millions of Americans are saddled with mounting student loan debt. Though some question whether college is worth the price, research has shown that having a college degree can significantly increase earning potential. There has been a more than 15 percent increase in the number of fundraisers for college students and related expenses on GoFundMe over the last year, a spokesperson told Newsweek. In 2024 alone, more than 40,000 people and organizations received donations on the platform to help with tuition fees and scholarships. "I think a lot of us are struggling," Brown, who works as a labor and postpartum doula, told Newsweek. She said that while some turn to their own communities for help, GoFundMe "is just a bigger platform to reach people." Brown said she raised almost $2,000 the first time she set up a GoFundMe page to help fund her education last year. She recently set up another account to help cover her tuition for the coming year, about $5,000 per quarter. On the page, she tells prospective donors that they would be investing in a future nurse "who will show up for the people who need it most." "My journey to nursing hasn't been easy. I've faced financial hardships, worked multiple jobs, and balanced life's responsibilities, all while showing up for patients, classmates, and my community," she wrote. "As a doula in East Nashville, I've seen firsthand the disparities Black women face in health care-especially in birth and postpartum care. That's why I'm not just going into nursing for a job-I'm answering a calling." She "can't do it alone," she added. "Tuition, books, and transportation cost are piling up. Unfortunately, financial aid hasn't been an option I could utilize this past quarter. That's why I'm asking for your help. Every donation-no matter the size-gets me one step closer to the finish line." Brown said she hadn't expected many donations when she first set up a fundraiser, but was pleasantly surprised by the support it received from people across the country. "The first time I did it, I didn't expect a lot of people to help just because they were strangers to me," she said. "A lot of people that donated lived in different states, and they were sending me emails and messages about how much they understood what I was going through, because they went through their own nursing journey. It's been pretty helpful." Dejonte Campbell, an 18-year-old living in New York City, also set up a GoFundMe page to raise money to support his pursuit of a degree in electrical engineering at Syracuse University. "I've been blessed with the opportunity to go to college to pursue a career in Electrical Engineering, something I've dreamed about for years," Campbell wrote on his page. "But as excited as I am, financial barriers are standing in the way. My mother has done everything she can, but college costs are far beyond what she can afford on her own. That's why I'm humbly asking for your help." Campbell told Newsweek that he initially set up the fundraiser after receiving less in financial aid than he needed to cover his tuition and expenses. After appealing, he can now cover his initial costs, but he is hopeful that the fundraiser will help him raise enough to pay for expenses over his four years of college. His friends had initially thought he was joking when he said he was going to set up a GoFundMe page, he said. "After a while, they realized I was serious, and I started promoting it more. My mom and my family started promoting it more, and I got a lot of donations from people from different parts of the country." He added: "I'm really grateful for the people who went out their way to donate to my GoFundMe because it shows that there's a lot of good people out there that really want to see people succeed." Brown said she thinks more students are utilizing platforms like GoFundMe because social media makes it easier to reach a huge audience. "You're more prone to being helped by a stranger rather than someone in your very own community, and I believe it's because of the reach that it has now," she said. "I could post a video or something on social media, and it'll be viral by the end of the week. So I think people are just reaching more communities via social media than word of mouth." She said she is grateful to those who have donated or raised awareness about fundraisers set up by her and others. "At this point, this GoFundMe hasn't just become about me like," she added. "I'm helping advocate for other students that may be struggling." Melanie Standage, a spokesperson for GoFundMe, told Newsweek that the platform's mission "is to help people help each other, and we're inspired by the generosity of those who come to the platform to help the next generation pursue their college dreams." She added, "Over the past 15 years, we've seen countless students' lives changed for the better thanks to the generosity of strangers. Whether they're the first in their family to attend college or are facing unexpected financial challenges, these students are harnessing the power of community to make their goals a reality, and we're proud to provide a platform that makes that possible." Campbell said he thinks students like him are turning to GoFundMe to ensure they have the opportunity to pursue the degrees that will give them the best chance of future success. "A lot of people out there, and a lot of like kids and teenagers out there, don't have the opportunity most of us have," he said. "So I feel like the ones that do have it and want better for themselves should get the opportunity to do better." For him, donations toward his tuition expenses will help him achieve the means to repay his mother for the sacrifices she has made for him and his siblings. He described her as a "courageous immigrant woman" who "left everything behind in search of a better future for me and my siblings" on his page. "Since then, she has worked not one, but two jobs day and night just to keep food on the table and help me stay in school," he said. To make her proud, he wants to become "a leader, a role model, and someone who lifts others the way I've been lifted by love, community, and faith." Though he knows getting his college degree isn't easy, he told Newsweek: "I'm still gonna push through and try my best. So at the end, I could reap what I sow." Related Articles Harvard Finds International Student Lifeline Amid Trump Visa ShowdownChina Military Unveils Mosquito-Sized Drones for 'Special Missions'College Degrees With Best Financial Return RevealedUtah College Student Says ICE Agent Who Detained Her 'Knew It Wasn't Right' 2025 NEWSWEEK DIGITAL LLC.
USA Today
6 hours ago
- USA Today
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5% The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a period intended to last 30 days, per the study protocol, but were promptly placed back on daily crofelemer treatment because their symptoms worsened Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that initial proof-of-concept results show that a novel liquid formulation of crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in a third intestinal failure patient. This is the second pediatric patient with intestinal failure due to the orphan disease short bowel syndrome (SBS-IF) who was treated with crofelemer. To date, three patients with intestinal failure due to SBS-IF or microvillus inclusion disease (MVID) have been treated with crofelemer in this exploratory, single-arm open label non-randomized IIT in Abu Dhabi. As announced, and as presented April 26, 2025 at the Annual ELITE PED-GI Congress, initial proof-of-concept results from this study show that crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, reduced the required TPN and supplementary intravenous fluids in the first participating MVID patient by up to 27% and in the first participating SBS-IF patient by up to 12.5%. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output – an indicator of improved nutrient oral absorption. 'We're very pleased to report that the second pediatric SBS-IF patient participating in this IIT exhibited a similar response for TPN reduction, further exemplifying that crofelemer's paradigm-shifting antisecretory mechanism of action may have the potential to provide a novel therapeutic option to modify disease progression due to the reductions in TPN and associated comorbidities in MVID and SBS-IF patients and improve their quality of life,' said Lisa Conte, Jaguar's Founder and CEO. 'This SBS-IF patient was administered the highest dose of crofelemer provided for in the approved protocol for the IIT, with no resulting safety issues.' Per the IIT protocol, as announced, the initial pediatric MVID patient participating in the study was taken off crofelemer after 12 weeks of treatment for an intended period of 30 days. However, after just 8 days, the patient's parents requested reinitiation of crofelemer dosing, as the patient's symptoms worsened – evidenced by increased stool output and decreased urine output – and the patient was restarted on daily treatment with crofelemer. The initial pediatric SBS-IF patient participating in the study also had crofelemer withdrawn per the protocol after 12 weeks. This patient then exhibited a relapse of symptoms and was put back on daily treatment with crofelemer, and has since been maintaining a significant TPN reduction. Jaguar plans to continue supplying crofelemer to Dr. Mohamad Miqdady, the principal investigator for this IIT, for the patients participating in this study for as long as Dr. Miqdady feels is medically necessary. Dr. Miqdady has submitted initial proof-of-concept data from the ongoing IIT in Abu Dhabi for all three above-referenced patients to a major international pediatric gastroenterological conference for consideration for presentation. Jaguar, through Jaguar family companies Napo and Napo Therapeutics, is currently supporting two independent proof-of-concept IITs, and conducting two placebo-controlled Phase 2 studies, of crofelemer in patients with intestinal failure due to MVID and SBS-IF in the United States, European Union, and/or Middle East/North Africa regions. Completion of Napo's randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients is expected in mid-2026 as planned. 'Our strategy is to seek business development partnerships for license rights for development and commercialization of Jaguar's intestinal failure products – with the goal of generating non-dilutive funding for Jaguar,' said Conte. 'Given the ultrarare nature of MVID, and the groundbreaking initial proof-of-concept results from the ongoing IIT in Abu Dhabi, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval.' Based on the initial findings of the ongoing IIT in Abu Dhabi, crofelemer's paradigm-shifting antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in patients with intestinal failure due to MVID and short bowel syndrome. The observed groundbreaking TPN reduction is particularly compelling for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management and for which no approved drug treatments exist, or any potential approach to reduce TPN. The initial proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) PRIME program that may accelerate regulatory approval pathways in the EU for this indication. This data may also support qualification of crofelemer for the FDA's Breakthrough Therapy program for expedited regulatory approval in the US. Additional proof-of-concept results from IITs are expected throughout 2025 and will provide additional preliminary data on the safety and potential effectiveness of crofelemer for these highly unmet clinical needs. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions. The IIT in Abu Dhabi is being conducted by Dr. Miqdady at Sheikh Khalifa Medical City (SKMC), a flagship tertiary hospital in the United Arab Emirates and the largest teaching medical center in Abu Dhabi. Dr. Miqdady, a recognized leader in pediatric gastroenterology, serves as the Chief of Pediatric Gastroenterology, Hepatology and Nutrition at SKMC. He is an American board-certified pediatric GI, hepatology and nutrition professor at Khalifa University in Abu Dhabi, and also serves as a member of Napo's Scientific Advisory Board. Dr. Miqdady completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children's Hospital in Houston. About Crofelemer Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as 'dragon's blood,' of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative(ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding Jaguar's expectation that completion of Napo's Phase 2 study of crofelemer in pediatric MVID patients will occur mid-2026, Jaguar's expectation that its strategy of seeking business development partnerships for license rights for development and commercialization of Jaguar's intestinal failure products may support generation of non-dilutive funding for Jaguar, Jaguar's expectation that even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval of crofelemer for MVID, Jaguar's expectation that crofelemer's mechanism of action may have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in pediatric MVID and SBS-IF patients, Jaguar's expectation that proof-of-concept data in MVID may support crofelemer's potential inclusion in the EMA's PRIME program for expediated and assisted regulatory approval and in the FDA's Breakthrough Therapy program for expedited regulatory approval in the US, Jaguar's expectation that additional proof-of-concept results from IITs will be available throughout 2025, and Jaguar's expectation that published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for MVID and SBS-IF. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc. View the original press release on ACCESS Newswire
